Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains

Jessica A. O'Hara, Lauretta A. Ambe, Leila G. Casella, Bethany M. Townsend, Mark R. Pelletier, Robert K. Ernst, Robert M.Q. Shanks, Yohei Doi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Treatment of infections due to extensively drug-resistant (XDR) Acinetobacter baumannii often involves the use of antimicrobial agents in combination. Various combinations of agents have been proposed, with colistin serving as the backbone in many of them. Recent data suggest that glycopeptides, in particular vancomycin, may have unique activity against laboratory-adapted and clinical strains of A. baumannii, alone and in combination with colistin. The aim of the present study was to test this approach against three unique colistin-resistant A. baumannii clinical strains using combinations of vancomycin (VAN), colistin (COL), and doripenem (DOR). All three strains possessed the signature phosphoethanolamine modification of the lipid A moiety associated with colistin resistance and unique amino acid changes in the PmrAB two-component signal transduction system not observed in colistin-susceptible strains. In checkerboard assays, synergy (defined as a fractional inhibitory concentration index [FICI] of<0.5) was observed between COL and VAN for all three strains tested and between COL and DOR in two strains. In time-kill assays, the combinations of COL-DOR, COL-VAN, and COL-DOR-VAN resulted in complete killing of colistin-resistant A. baumannii in 1, 2, and all 3 strains, respectively. In the Galleria mellonella moth model of infection, the combinations of DOR-VAN and COL-DOR-VAN led to significantly increased survival of the larvae, compared with other combinations and monotherapy. These findings suggest that regimens containing vancomycin may confer therapeutic benefit for infection due to colistin-resistant A. baumannii.

Original languageEnglish
Pages (from-to)2103-2108
Number of pages6
JournalAntimicrobial agents and chemotherapy
Volume57
Issue number5
DOIs
Publication statusPublished - 01-05-2013

Fingerprint

Colistin
Acinetobacter baumannii
Vancomycin
doripenem
Infection
Lipid A
Glycopeptides
Moths
Anti-Infective Agents

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

O'Hara, Jessica A. ; Ambe, Lauretta A. ; Casella, Leila G. ; Townsend, Bethany M. ; Pelletier, Mark R. ; Ernst, Robert K. ; Shanks, Robert M.Q. ; Doi, Yohei. / Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. In: Antimicrobial agents and chemotherapy. 2013 ; Vol. 57, No. 5. pp. 2103-2108.
@article{29ace83747044361ab0f1547df5f855a,
title = "Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains",
abstract = "Treatment of infections due to extensively drug-resistant (XDR) Acinetobacter baumannii often involves the use of antimicrobial agents in combination. Various combinations of agents have been proposed, with colistin serving as the backbone in many of them. Recent data suggest that glycopeptides, in particular vancomycin, may have unique activity against laboratory-adapted and clinical strains of A. baumannii, alone and in combination with colistin. The aim of the present study was to test this approach against three unique colistin-resistant A. baumannii clinical strains using combinations of vancomycin (VAN), colistin (COL), and doripenem (DOR). All three strains possessed the signature phosphoethanolamine modification of the lipid A moiety associated with colistin resistance and unique amino acid changes in the PmrAB two-component signal transduction system not observed in colistin-susceptible strains. In checkerboard assays, synergy (defined as a fractional inhibitory concentration index [FICI] of<0.5) was observed between COL and VAN for all three strains tested and between COL and DOR in two strains. In time-kill assays, the combinations of COL-DOR, COL-VAN, and COL-DOR-VAN resulted in complete killing of colistin-resistant A. baumannii in 1, 2, and all 3 strains, respectively. In the Galleria mellonella moth model of infection, the combinations of DOR-VAN and COL-DOR-VAN led to significantly increased survival of the larvae, compared with other combinations and monotherapy. These findings suggest that regimens containing vancomycin may confer therapeutic benefit for infection due to colistin-resistant A. baumannii.",
author = "O'Hara, {Jessica A.} and Ambe, {Lauretta A.} and Casella, {Leila G.} and Townsend, {Bethany M.} and Pelletier, {Mark R.} and Ernst, {Robert K.} and Shanks, {Robert M.Q.} and Yohei Doi",
year = "2013",
month = "5",
day = "1",
doi = "10.1128/AAC.02501-12",
language = "English",
volume = "57",
pages = "2103--2108",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

O'Hara, JA, Ambe, LA, Casella, LG, Townsend, BM, Pelletier, MR, Ernst, RK, Shanks, RMQ & Doi, Y 2013, 'Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains', Antimicrobial agents and chemotherapy, vol. 57, no. 5, pp. 2103-2108. https://doi.org/10.1128/AAC.02501-12

Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. / O'Hara, Jessica A.; Ambe, Lauretta A.; Casella, Leila G.; Townsend, Bethany M.; Pelletier, Mark R.; Ernst, Robert K.; Shanks, Robert M.Q.; Doi, Yohei.

In: Antimicrobial agents and chemotherapy, Vol. 57, No. 5, 01.05.2013, p. 2103-2108.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains

AU - O'Hara, Jessica A.

AU - Ambe, Lauretta A.

AU - Casella, Leila G.

AU - Townsend, Bethany M.

AU - Pelletier, Mark R.

AU - Ernst, Robert K.

AU - Shanks, Robert M.Q.

AU - Doi, Yohei

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Treatment of infections due to extensively drug-resistant (XDR) Acinetobacter baumannii often involves the use of antimicrobial agents in combination. Various combinations of agents have been proposed, with colistin serving as the backbone in many of them. Recent data suggest that glycopeptides, in particular vancomycin, may have unique activity against laboratory-adapted and clinical strains of A. baumannii, alone and in combination with colistin. The aim of the present study was to test this approach against three unique colistin-resistant A. baumannii clinical strains using combinations of vancomycin (VAN), colistin (COL), and doripenem (DOR). All three strains possessed the signature phosphoethanolamine modification of the lipid A moiety associated with colistin resistance and unique amino acid changes in the PmrAB two-component signal transduction system not observed in colistin-susceptible strains. In checkerboard assays, synergy (defined as a fractional inhibitory concentration index [FICI] of<0.5) was observed between COL and VAN for all three strains tested and between COL and DOR in two strains. In time-kill assays, the combinations of COL-DOR, COL-VAN, and COL-DOR-VAN resulted in complete killing of colistin-resistant A. baumannii in 1, 2, and all 3 strains, respectively. In the Galleria mellonella moth model of infection, the combinations of DOR-VAN and COL-DOR-VAN led to significantly increased survival of the larvae, compared with other combinations and monotherapy. These findings suggest that regimens containing vancomycin may confer therapeutic benefit for infection due to colistin-resistant A. baumannii.

AB - Treatment of infections due to extensively drug-resistant (XDR) Acinetobacter baumannii often involves the use of antimicrobial agents in combination. Various combinations of agents have been proposed, with colistin serving as the backbone in many of them. Recent data suggest that glycopeptides, in particular vancomycin, may have unique activity against laboratory-adapted and clinical strains of A. baumannii, alone and in combination with colistin. The aim of the present study was to test this approach against three unique colistin-resistant A. baumannii clinical strains using combinations of vancomycin (VAN), colistin (COL), and doripenem (DOR). All three strains possessed the signature phosphoethanolamine modification of the lipid A moiety associated with colistin resistance and unique amino acid changes in the PmrAB two-component signal transduction system not observed in colistin-susceptible strains. In checkerboard assays, synergy (defined as a fractional inhibitory concentration index [FICI] of<0.5) was observed between COL and VAN for all three strains tested and between COL and DOR in two strains. In time-kill assays, the combinations of COL-DOR, COL-VAN, and COL-DOR-VAN resulted in complete killing of colistin-resistant A. baumannii in 1, 2, and all 3 strains, respectively. In the Galleria mellonella moth model of infection, the combinations of DOR-VAN and COL-DOR-VAN led to significantly increased survival of the larvae, compared with other combinations and monotherapy. These findings suggest that regimens containing vancomycin may confer therapeutic benefit for infection due to colistin-resistant A. baumannii.

UR - http://www.scopus.com/inward/record.url?scp=84876209645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876209645&partnerID=8YFLogxK

U2 - 10.1128/AAC.02501-12

DO - 10.1128/AAC.02501-12

M3 - Article

C2 - 23422916

AN - SCOPUS:84876209645

VL - 57

SP - 2103

EP - 2108

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -